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Overview of Legislative and 
Regulatory Landscape 
Statutory & Regulatory Landscape 
 at Federal and State Levels 
◄ EPA, TSCA & FIFRA 
– ―plugged in‖ both internationally (e.g., ISO; 
OECD) and domestically (e.g., California 
DTSC activities) 
– CNT and Nano Initiatives 
– EPA Nanotechnology White Paper 
– Nanosilver and recent CNT SNUR 
◄ FDA 
◄ NIOSH 
◄ USDA 
 
TSCA – Chemical Substances 
◄ §5 – ―New Chemicals‖ 
(―R&D‖ important to note) 
◄ §4 – Testing 
◄ §8 – Information gathering 
– Reports 
– Records 
– Information and data call-In 
◄ §6 – Regulatory actions/restrictions 
◄ §12/13 – Export/Imports 
◄ Other §§ – Addressing other areas, notably, 
enforcement and §15(2) 
Evolution of EPA and Congressional 
Action – TSCA 
◄ CNT SNURs 
◄ Safe Chemicals Act of 2011 - Introduced 4/14/11 
– Burden of proof on manufacturer to prove  
chemical meets safety standard before  
chemicals allowed to reach the market 
◄ ―The Administration shall . . . find that a chemical substance  
meets the safety standard only if the Administrator finds  
that there is a reasonable certainty that no harm will result  
to human health or the environment from aggregate exposure 
to the chemical substance.‖ 
– Safety testing ―as a condition‖ for allowing  
distribution of the chemical  
– EPA to prioritize chemicals based on risk 
– Expedited risk management of persistent,  
bioaccumulative and toxic chemicals 
– Public database 
 
 
FIFRA – Pesticides 
◄ Includes:  Insecticides, Fungicides, Herbicides, 
Rodenticides, and Antimicrobials 
◄ § 3–Registration 
◄ § 5–Experimental Uses 
◄ §17–Exports and Imports 
FIFRA – Pesticides 
◄ EPA’s Office of Pesticide Programs intends to confirm 
that nanoscale versions of existing registered active 
ingredients are ―new‖ pesticides that require registration 
under FIFRA section 3. 
– Regardless of whether a non-nanoscale form  
of the same active or inert ingredient is already  
registered under FIFRA 
– Nanosilver considered a new  
pesticide, even though silver is already  
registered as a pesticide. 
FIFRA – Pesticides 
◄ Rumored revisions to interpretation of  
FIFRA Section 6(a)(2) (―adverse effects‖  
section) – no formal proposed revisions yet 
– Currently requires pesticide product registrants to submit  
adverse effects information about their products to the EPA  
– EPA: new interpretation would likely: 
◄ Require pesticide manufacturers to report the deliberate inclusion of 
intentionally produced nanomaterials in their products 
◄ Emphasize data collection, while also including adverse effects 
◄ Reach substances other than nanomaterials 
FDA: Proposed Legislation 
◄ H.R. 5786, Safe Cosmetics Act of 2010 – died in  
committee, but could be reintroduced 
– Phase-out of ingredients linked to cancer, birth defects and  
developmental harm; 
– Elimination of labeling loopholes by requiring full ingredient  
disclosure on product labels and company web sites; 
– Worker access to information about unsafe chemicals in personal  
care products; 
– Data-sharing to avoid duplicative testing and encourage  
the development of alternatives to animal testing 
– Safety standard similar to the standard purposed in  
Toxic Chemicals Safety Act of 2010: 
 ―With respect to an ingredient when the route of exposure directly 
relates to a particular cosmetic use, a standard that— provides  
a reasonable certainty that no harm will result from aggregate exposure to the cosmetic 
or ingredient, including impacts on vulnerable populations, taking into account possible 
harmful effects from low dose exposures to the cosmetic or ingredient or from additive 
effects, where such evidence exists…‖ 
NIOSH 
◄ National Institute for Occupational Safety and Health set 
Recommended Exposure Limits (RELs) for fine and ultrafine 
titanium dioxide 
– exposure limit for ultrafine titanium dioxide is the first REL applied to 
nanoparticles 
– REL imposed because of in vitro  
and in vivo studies in animals  
(rodent inhalation and ingestion  
studies) suggesting the genotoxicity  
of titanium dioxide is related to  
particle surface area rather than  
the compound itself 
◄ More regulation of  
nanomaterials, based on particle  
size, likely soon 
OEHHA Recommendations 
◄ May 4, 2011: ―Recommendations for Addressing Potential Health 
Risks from Nanomaterials in California,‖ Commissioned by 
California's Office of Environmental Health Hazard Assessment  
(OEHHA) 
– Recommendations to address health risks from nanomaterials for 
OEHHA that can be achieved under the existing regulatory structure 
(e.g., develop a definition of nanomaterials; define, identify and collect 
information regarding priority properties for risk characterization, fate 
and transport of nanomaterials; etc.) 
– Recommendations to support successful approaches to address 
potential health risks from nanomaterials that are currently outside the 
scope of OEHHA (e.g., require disclosure of where and what 
nanomaterials are manufactured, in what quantities, and for what new 
or existing products; reporting and disclosure requirements; testing 
requirements; etc.) 
◄ http://www.prhe.ucsf.edu/prhe/nanodocument.html 
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Leahy-Smith American Invents Act 
 
The day everything changed 
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September 26, 2011 
Leahy-Smith American Invents Act 
Enacted 16 Sept. 2011 
 
What People Are Saying 
◄ This much-needed reform will speed up the patent process so that 
innovators and entrepreneurs can turn a new invention into a 
business as quickly as possible‖ 
      - President Obama 
◄ The America Invents Act brings the U.S. patent system into the 21st 
century and will help speed and expand the innovation capacity of 
the American economy, creating new technologies, products and 
jobs.  
    - Ellen Kullman, CEO DuPont 
◄ [AIA] actually represents an effort by multinational and foreign 
corporations to crush America’s vital culture of independent 
inventors.  
    - Robert Zubrin, Washington Times 
◄ ―The America Invents Act is a true jobs bill at a time when we need it 
the most.‖ 
    - Senator Leahy 
First Take Aways 
◄ First-to-file (sort of) 
– Derivative Actions and Procedural Loophole 
◄ Tiered Implementation stretching over 18 months 
– Effectively creates a dual system stretching into the 2030’s 
◄ Fees – 15% surcharge today 
– Micro-entity status / Universities and most non-profits 
◄ Patent marking – Qui Tam essentially dead 
◄ No joinder of multiple defendants in infringement action  
Timeline for Enactment 
 
+0 days 
Sept. 16, 2011 
+10 days 
Sept. 26, 2011 
+60 days 
Nov. 15, 2011 
+12 months 
Sept 16, 2012 
+18 months 
March 16, 2012 
Re-examination 
threshold – 
higher – 
Reasonable 
likelihood  
Tax strategies – 
verboten 
Best mode invalidity – 
gone 
Virtual marking – 
allowed via web 
False marking – Qui 
Tam suites are 
gone 
 
Prioritized Examination 
– 10k cases 
maximum 
$4800 fee 
limited claims 
Answer in 12 
months 
15% surcharge is 
effective 
Electronic filing 
incentive - $400 
penalty for filing 
on paper 
Inventor’s 
Oath/Declaration 
– easier for 
company to file if 
inventor is MIA 
3rd Party submission of 
prior art for 
patent 
application 
Supplemental 
Examination 
Citation of prior art in 
patent file 
Priority examination 
for important 
technologies 
Post-grant review 
Transitional post-grant 
review program 
First Inventor to File – 
the flood gates 
open 
Derivation proceedings 
– Modified first-
to-file system 
Rule making has started – USPTO 
requests early feedback.   
Zeroth Day 
◄ Re-examination – higher threshold 
– Reasonable likelihood that 
requester would prevail  
vs 
– OLD substantial new question of 
patentability  
◄ Best mode invalidity 
– Gone* – But see 35 USC 112,¶1 
◄ Virtual marking 
– Allowed via website 
◄ False marking  
– Qui Tam suites are gone 
◄ Tax strategies are automatically 
within the prior art 
Ten to Sixty Days 
◄ Prioritized examination today 
– 10,000 cases maximum 
– $4800 fee 
– limited claims (4 ind / 30 total) 
– Answer in 12 months 
◄ 15% surcharge is effective today 
– Fee diversion is ―gone‖* 
◄ Stop paper filing by  
November 15, 2011 
– $400 fee for filing by paper 
– EFS filing is easy and fast (now 
stable too) 
12 Months 
◄ Inventor’s Oath/Declaration 
– Easier for company to file if inventor is missing or unwilling to comply with 
obligations as inventor 
◄ Pre-grant submission of prior art for patent application 
– Allowed to submit prior art along with explanations 
◄ Priority examination for important technologies 
– Extend USPTO’s Green Tech program to other technologies – Class 977 
Nano?  
12 Months Continued 
Yes there is more 
◄ Post-grant opposition and review period 
– Post Grant Review - within 9 months after issuance – very broad scope 
◄ Threshold – ―more likely than not that 1 or more claims invalid‖ 
– Inter Partes Review – >9 months – prior art patents and printed publications 
◄ Threshold – ―reasonable likelihood would prevail‖ 
– Relationship to civil actions – bars Post and Inter Partes Review if previously filed 
civil action challenging validity (not counterclaim) and automatically stays civil 
actions filed after request filed 
– Ex Parte Reexamination – anytime after patent grant for prior art patents and 
printed publications  
◄ Supplemental Examination 
– Allows submission of prior art to USPTO to determine if prior art raises a significant 
new question of patentability 
◄ Transitional post-grant review program for business methods 
18 Months 
Beware the Ides of March 2013 
◄ First Inventor to File  
– Transition to first-inventor-to-file 
patent system while maintaining 1 
year grace for inventor disclosures 
– File on March 15, 2013 – New 
Applications; Continuations-in-
Part; Continuations with new 
claims disclosed but not claimed?  
◄ Derivation proceedings – Modified 
first-to-file system 
– Allows inventor who files later to 
challenge an earlier filed patent 
application because it is ―derived‖ 
from the inventor’s work 
 
◄ Prior Art – changed but similar 
– Patented 
– Described in printed publication 
– On sale  
– Otherwise available to the public 
– Also new 102(e) standards 
Leahy-Smith America Invents Act 
There is a lot more… 
 
But not for today  
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Nanotechnology Litigation In The Future 
 
Steps to Protect Your Company 
John R. Mitchell 
September 26, 2011 
Steps to Protect Your Company 
1. Recognize that one size does not fit all 
2. Be (or employ) an expert 
3. Be aware of existing and future regulations 
4. Consider voluntary disclosure 
5. Know the details of your insurance coverage 
6. Participate in organizations 
7. Take precautions 
1.  One Size Does Not Fit All 
◄ As we know, nanomaterials can vary tremendously in size, shape, 
structure, reactivity, etc. 
◄ The toxicology studies involve varying sizes of particles, levels of 
exposure, duration of exposure, types of laboratory animals, and 
results 
◄ Plaintiffs often try to group diverse 
products under one umbrella to take  
advantage of existing studies or  
negative publicity 
◄ Distinguish your products and prepare  
a course of action specific to your  
products and your company 
 
 
2.  Be (or Employ) an Expert 
◄ Two key factors of product liability law: 
 a.  Manufacturers are responsible for warning of dangers they 
know or have reason to know 
 b.  Manufacturers are held to have the level of      
knowledge of an expert in their field 
◄ It is critical to have knowledgeable and  
adequately trained people to monitor the  
state-of-the-art 
◄ You will not get the benefit of the doubt later 
 
3. Be Aware of Regulations 
◄ Federal, state, and foreign governments are all 
regulating products containing nanomaterials 
◄ As seen above, no clear cut consensus exists with 
regard to the manner in which nanomaterials will be 
regulated in the United States, Europe, or elsewhere 
 
4.  Consider Voluntary Disclosure 
  
Question::  If a company is not  
under any legal obligation to  
disclose information about its use  
of nanomaterials, why should it  
consider voluntary disclosure?  
 Answer::  Courts and juries looking in hindsight may 
decide that companies should have provided warnings 
despite absence of mandatory disclosures. 
 
 
4.  Consider Voluntary Disclosure 
 
◄ Deciding whether to disclose information or warn is a 
VERY difficult question 
– False Alarms - Past epidemiology and toxicology 
studies can be proven wrong as science develops 
  
– Providing warnings under such circumstances could 
promote unnecessary fear and anxiety in workforce 
 
4.  Consider Voluntary Disclosure 
 
◄ Deciding what information to provide is a VERY difficult 
question 
– Effective warning typically  
provides: 
◄ Warning language  
(―DANGER,‖ ―HAZARD‖) 
◄ Instruction on what to avoid 
◄ Potential consequences 
– Creating an effective warning becomes difficult when the state-
of-the-art is constantly changing and so little is known 
 
5.  Understand Your Insurance 
Coverage 
◄ The insurance industry is paying 
attention 
◄ Several attempts to exclude coverage  
for anything related to nanotechnology  
(as opposed to raising deductibles or  
setting coverage limits) 
◄ Review your insurance polices and  
consult an expert to make sure you  
are covered 
 
6.  Participation in Organizations 
◄ ANSI Nanotechnology Standards Panel advocates for uniform 
nanotechnology standards 
◄ ACC Nanotechnology Panel shares information and supports health 
and safety research 
◄ Benefits - Keep abreast of state-of-the-art; contribute to policy-
making discussions 
◄ Risks - Cost; potential civil conspiracy claims in future mass tort 
litigation 
 
7.  Take Precautions 
◄ Use industrial hygiene practices proven to be effective for fine 
particles (ventilation systems, respirators, other protective clothing, 
etc.) 
 
◄ Document the reasons behind your decisions to take (or not take) 
certain precautionary actions  
 
◄ Helps avoid punitive damage claims and prevent plaintiff’s lawyers 
and juries from speculating as to your motives 
 
◄ Consulting attorneys on these issues creates attorney-client 
privilege 
 
Conclusion 
◄ Stay abreast of current developments, research, 
and the ever-changing regulations 
◄ Be or employ toxicology, epidemiology, 
industrial hygiene, and warnings experts so that 
you can best protect your employees and 
customers 
◄ Consult with attorneys to develop strategies that 
are specific to YOUR products and processes 
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